Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2106-2112

  Bosso, John A ^a,b   Mauldin, Patrick D ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; DRUG FORMULARY; DRUG USE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RISK FACTOR; TIME SERIES ANALYSIS; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CROSS INFECTION; ESCHERICHIA COLI; FLUOROQUINOLONES; FORMULARIES; GRAM-NEGATIVE BACTERIA; HUMANS; METHICILLIN; METHICILLIN RESISTANCE; OFLOXACIN; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STAPHYLOCOCCUS AUREUS;

EID: 33744482028     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01359-05     Document Type: Article

References (51)

1. Abramson, M. A., and D. J. Sexton. 1999. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect. Control Hosp. Epidemiol. 20:408-411.
2. Bhavnani, S. M., W. A. Callen, A. Forrest, K. K. Gilliland, D. A. Collins, J. A. Paladine, and J. J. Schentag. 2003. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am. J. Health Syst. Pharm. 60:1962-1970.
3. Bisognano, C., P. E. Vaudaux, D. P. Lew, E. Y. Ng, and D. C. Hooper. 1997. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother. 41:906-913.
4. Bisognano, C., P. Vaudaux, P. Rohner, D. P. Lew, and D. C. Hooper. 2000. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother. 44:1428-1437.
5. Box, G. E. P., and G. Jenkins. 1976. Time series analysis: forecasting and control, revised edition. Holden Day, San Francisco, Calif.
6. Campillo, B., C. Dupeyron, and J. P. Richardet. 2001. Epidemiology of hospital-acquired infections in cirrhotic patients: effect on carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol. Infect. 127:443-450.
7. Carbon, C. 1999. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 44(Suppl. A):31-36.
8. Carmeli, Y., N. Troillet, A. W. Karchmer, and M. H. Samore. 1999. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. 159:1127-1132.
9. Cosgrove, S. E., and Y. Carmeli. 2003. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36:1433-1437.
10. Crowcroft, N. S., O. Ronveaux, D. L. Monnet, and R. Mertens. 1999. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect. Control Hosp. Epidemiol. 20:31-36.
11. Durbin, J., and G. S. Watson. 1951. Testing for serial correlation in least squares regression. II. Biometrika 38:159-178.
12. Dziekan, G., A. Hahn, K. Thüne, G. Schwarzer, K. Schäfer, F. Daschner, and H. Grundmann. 2000. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J. Hosp. Infect. 46:263-270.
13. Engemann, J. J., Y. Carmeli, S. E. Cosgrove, V. G. Fowler, M. Z. Bronstein, S. L. Trivette, J. P. Briggs, D. J. Sexton, and K. S. Kaye. 2003. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36:592-598.
14. Gilbert, D. N., S. J. Kohlhepp, K. A. Slama, G. Grunkemeier, G. Lewis, R. J. Dworkin, S. E. Slaughter, and J. E. Leggett. 2001. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob. Agents Chemother. 45:883-892.
15. Gillings, D., D. Makuc, and E. Siegel. 1981. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am. J. Public Health 71:38-46.
16. Graffunder, E. M., and R. A. Venezia. 2002. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. 49:999-1005.
17. Harbarth, S., N. Liassine, S. Dharan, P. Herrault, R. Auckenthaler, and D. Pillel. 2000. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 31:1380-1385.
18. Helfenstein, U. 1996. Box-Jenkins modelling in medical research. Stat. Methods Med. Res. 5:3-22.
19. Hill, D. A., T. Herford, and D. Parratt. 1998. Antibiotic usage and methicillin-resistant Staphylococcus aureus: an analysis of causality. J. Antimicrob. Chemother. 42:676-677.
20. Hoban, D. J., G. V. Doern, A. C. Fluit, M. Roussel-Delvallez, and R. N. Jones. 2001. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S81-S93.
21. Holmberg, S. D., S. L. Solomon, and P. A. Blake. 1987. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9:1065-1078.
22. Institute of Medicine. 1998. Antimicrobial resistance: issues and options. Workshop report. National Academy Press, Washington, D.C.
23. Jacoby, G. A. 2005. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41(Suppl. 2):S120-S126.
24. Karlowsky, J. A., D. C. Draghi, M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688.
25. Kern, W. V., M. Steib-Bauert, K. de With, S. Reuter, H. Bertz, U. Frank, and H. von Baum. 2005. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J. Antimicrob. Chemother. 55:57-60.
26. Lautenbach, E., B. L. Stron, W. B. Bilker, J. B. Patel, P. H. Edelstein, and N. O. Fishman. 2001. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin. Infect. Dis. 33:1288-1294.
27. Lautenbach, E., B. L. Strom, W. B. Bilker, A. M. Marr, L. A. Larosa, and N. O. Fishman. 2004. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin. Infect. Dis. 38:655-662.
28. Lautenbach, E., J. P. Metlay, W. B. Bilker, P. H. Edelstein, and N. O. Fishman. 2005. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections. The role of inadequate empirical antimicrobial therapy. Clin. Infect. Dis. 41:923-929.
29. Linden, P. K., A. W. Pasculle, R. Manez, D. J. Kramer, J. J. Fung, A. D. Pinna, and S. Kusne. 1996. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-sensitive Enterococcus faecium. Clin. Infect. Dis. 22:663-670.
30. Livermore, D. M., D. James, M. Reacher, C. Graham, T. Nichols, P. Stephens, A. P. Johnson, and R. C. George. 2002. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg. Infect. Dis. 8:473-479.
31. Lopez-Lozano, J. M., D. L. Monnet, A. Yague, A. Burgos, N. Gonzalo, P. Campillos, and M. Saez. 2000. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis. Int. J. Antimicrob. Agents 14:21-31.
32. MacDougall, C., J. P. Powell, C. K. Johnson, M. B. Edmond, and R. E. Polk. 2005. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin. Infect. Dis. 41:435-440.
33. MacDougall, C., S. E. Harpe, J. P. Powell, C. K. Johnson, M. B. Edmond, and R. E. Polk. 2005. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg. Infect. Dis. 11:1197-1204.
34. McGowan, J. E., Jr. 1987. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull. N. Y. Acad. Med. 63:253-268.
35. Mohr, J. F., A. Jones, L. Ostrosky-Zeichner, A. Wanger, and G. Tillotson. 2004. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int. J. Antimicrob. Agents 24:346-351.
36. Mol, P. G. M., J. E. Wieringa, P. V. NannanPanday, R. O. B. Gans, J. E. Degener, M. Laseur, and F. M. Haaijer-Ruskamp. 2005. Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis. J. Antimicrob. Chemother. 55:550-557.
37. Monnet, D. L. 1998. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect. Control Hosp. Epidemiol. 19:552-559.
38. Monnet, D. L., J. M. Lopez-Lozano, P. Campillos, A. Burgos, A. Yague, and N. Gonzalo. 2001. Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models. Clin. Microbiol. Infect. 7(Suppl. 5):29-36.
39. Monnet, D. L., F. M. Mackenzie, J. M. Lopez-Lozano, A. Beyaert, M. Camacho, R. Wilson, D. Stuart, and I. M. Gould. 2004. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg. Infect. Dis. 10:1432-1441.
40. Muder, R. R., C. Brennen, A. M. Goetz, M. M. Wagener, and J. D. Rihs. 1991. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs Medical Center. Antimicrob. Agents Chemother. 35:256-258.
41. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885-888.
42. Paramythiotou, E., J. C. Lucet, J. F. Timsit, D. Vanjak, C. Paugam-Burtz, J. L. Trouillet. S. Belloc, N. Kassis, A. Karabinis, and A. Andremont. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: roles of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677.
43. Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, S. Mohapatra, G. M. Trenholme, K. P. Klugman, J. G. McCormack, and V. L. Yu. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis. 30:473-478.
44. Péna, C., J. M. Albareda, R. Pallares, M. Pujol, F. E. Tubau, and J. Ariza. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:520-524.
45. Polk, R. E., C. K. Johnson, D. McClish, R. P. Wenzel, and M. B. Edmond. 2004. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin. Infect. Dis. 39:497-503.
46. Rello, J., A. Torres, M. Ricart, J. Valles, J. Gonzalez, A. Artigas, and R. Rodriguez-Roisin. 1994. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am. J. Respir. Crit. Care Med. 150:1545-1549.
47. Thomas, J. K., A. Forrest, S. M. Bhavnani, J. M. Hyatt, A. Cheng, C. H. Ballow, and J. J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
48. Venezia, R. A., B. E. Domaracki, A. M. Evans, K. E. Preston, and E. M. Graffunder. 2001. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J. Antimicrob. Chemother. 48:375-381.
49. Weber, S. G., H. S. Gold, D. C. Hooper, A. W. Karchmer, and Y. Carmeli. 2003. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9:1415-1422.
50. Wenzel, R. P., D. F. Sahm, C. Thornsberry, D. C. Draghi, M. E. Jones, and J. A. Karlowsky. 2003. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob. Agents Chemother. 47:3089-3098.
51. Zervos, M. J., E. Hershberger, D. P. Nicolau, D. J. Ritchie. L. K. Blackner, E. A. Coyle, A. J. Donnelly, S. F. Eckel, R. H. Eng, A. Hiltz, A. G. Kuyumjian, W. Krebs, A. McDaniel, P. Hogan, and T. J. Lubowski. 2003. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin. Infect. Dis. 37:1643-1648.